International Biotechnology Trust PLC - London-based investment trust managed by SV Health Managers LLP - Company corrects that, for the six months that ended February 28, its net asset value per share total return was negative 15%, rather than the 13% reported on Wednesday, while the company's benchmark, the Nasdaq Biotechnology Index, returned negative 23%. The correction to the return relates to dividends paid. The trust swung to a pretax loss of GBP48.5 million in the six months from a profit of GBP19.1 million a year previous. International Biotechnology Trust makes a GBP46.5 million loss on investments, versus a gain of GBP20.4 million a year before. NAV per share stands at 648.82 pence at February 28, down from 775.73p a year previous. Says the biotechnology sector has experienced a "significant" period of weakness, but the company's outlook remains positive.
Current stock price: 612.00p
12-month change: down 13%
By Tom Waite; thomaslwaite@alliancenews.com
Copyright 2022 Alliance News Limited. All Rights Reserved.
Int.biotech. (IBT)